The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Employee advances | - | - | -41,852 | 0 |
| Accounts payable | - | 6,562,097 | 671,563 | 1,040,656 |
| Net loss | -10,396,831 | -13,460,833 | -6,879,530 | -8,413,481 |
| Depreciation and amortization expense | 124,938 | 124,938 | 124,938 | 113,209 |
| Amortization of debt issuance costs and warrants | 68,972 | 0 | - | - |
| Shares issued for services | 289,200 | 0 | 239,253 | 356,588 |
| Stock-based compensation expense | 1,435,362 | 1,604,560 | 814,932 | 1,846,465 |
| Shares issued for services | - | 0 | - | - |
| Prepaid expenses | -63,082 | -340,131 | -348,750 | -348,750 |
| Amortization of debt discounts issuance and warrants | - | - | 0 | 0 |
| Shares issued for interest expense | - | 0 | - | - |
| Accounts payable and accrued expenses | 3,882,449 | 1,019,552 | 15,140 | -140,700 |
| Accrued interest on convertible notes | -6,372 | 0 | 0 | 0 |
| Accrued payroll and payroll taxes | -37,082 | 37,457 | 614 | -97,257 |
| Change in value of warrant liabilities | - | - | 0 | -1,424,603 |
| Changes in fair value of warrant liability | 0 | 0 | - | - |
| Commitment shares issued for equity line of credit | 0 | 0 | 0 | 568,235 |
| Net cash used in operating activities | -4,563,538 | -3,730,246 | -4,706,192 | -5,802,138 |
| Proceeds from warrant exercises (net of issuance costs) | 3,376,260 | 530,162 | - | - |
| Deferred offering costs | - | - | - | 0 |
| Common stock issuance (net of fees) | - | 1,593,870 | 3,780,805 | 2,483,465 |
| Sale of preferred stock | - | -582 | 0 | 1,053,582 |
| Short-term borrowings | - | 0 | 0 | 0 |
| Short-term loan repayments | - | 0 | 0 | - |
| Initial public offering (net of fees) | - | 0 | 0 | - |
| Proceeds from convertible notes (net of issuance costs) | 1,835,000 | 0 | 0 | 0 |
| Sale of preferred stock and warrants | 0 | - | - | - |
| Net cash provided by financing activities | 5,211,260 | 2,123,450 | 3,780,805 | 3,537,047 |
| Shareholder loan repayment | 0 | - | - | - |
| Patent license acquisition | 0 | 0 | 0 | 466,423 |
| Net cash used in investing activities | 0 | 0 | 0 | -466,423 |
| Net change in cash and cash equivalents | 647,722 | -1,606,796 | -925,387 | -2,731,514 |
| Cash and cash equivalents beginning of period | 269,830 | 1,876,626 | 5,533,527 | - |
| Cash and cash equivalents end of period | 917,552 | 269,830 | 1,876,626 | - |
OS Therapies Inc (OSTX)
OS Therapies Inc (OSTX)